Download PDF
Semin Thromb Hemost 2014; 40(02): 205-213
DOI: 10.1055/s-0033-1364188
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Biological Standards for Potency Assignment to Fibrinolytic Agents Used in Thrombolytic Therapy

Craig Thelwell
1   Biotherapeutics, Haemostasis Section, National Institute for Biological Standards and Control, South Mimms, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
30 January 2014 (online)

    Permissions and Reprints

Abstract

Thrombolytic drugs are used for the treatment of thrombotic disorders such as acute myocardial infarction, acute ischemic stroke, and pulmonary embolism. Biological standards are used for potency assignment to the range of fibrinolytic proteins used in thrombolytic therapy. The World Health Organization (WHO) International Standards are primary reference materials, calibrated in arbitrary units (international unit), assigned by collaborative study using the range of assay methods available at the time. Provided the standard and test material are equivalent, adhering to the principle of measuring like versus like, the exact nature of the assay method is unimportant. This approach has been applied successfully for several decades since the advent of fibrinolytic treatment, ensuring consistency for potency labeling and the correct dosing of patients. The emergence of generic biosimilar products and new recombinant variants poses a challenge to this system, where functional differences impact on the relative biological activity in different assay systems. A more demanding system of standardization may therefore be required on the basis of international reference materials with associated reference methods. WHO recognizes this, and where possible and practical is seeking to incorporate concepts of traceability, uncertainty, and commutability to International Standards. However, some caution is needed because limitations on the characterization of many complex biologicals remain real, and a flexible approach is required on the basis of real-world needs.

Keywords

thrombolytic agents - biological standards - international unit - international reference material
 

  • References

  • 1 Global status report on noncommunicable diseases 2010. World Health Organisation; 2011
    Google Scholar
  • 2 Kunadian V, Gibson CM. Thrombolytics and myocardial infarction. Cardiovasc Ther 2012; 30 (2) e81-e88
    CrossrefPubMedGoogle Scholar
  • 3 Medcalf RL, Davis SM. Plasminogen activation and thrombolysis for ischemic stroke. Int J Stroke 2012; 7 (5) 419-425
    CrossrefPubMedGoogle Scholar
  • 4 Tapson VF. Thrombolytic therapy in acute pulmonary embolism. Curr Opin Cardiol 2012; 27 (6) 585-591
    CrossrefPubMedGoogle Scholar
  • 5 Flemmig M, Melzig MF. Serine-proteases as plasminogen activators in terms of fibrinolysis. J Pharm Pharmacol 2012; 64 (8) 1025-1039
    CrossrefPubMedGoogle Scholar
  • 6 Wicky S, Pinto EG, Oklu R. Catheter-directed thrombolysis of arterial thrombosis. Semin Thromb Hemost 2013; 39 (4) 441-445
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Oklu R, Wicky S. Catheter-directed thrombolysis of deep venous thrombosis. Semin Thromb Hemost 2013; 39 (4) 446-451
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Lippi G, Mattiuzzi C, Favaloro EJ. Novel and emerging therapies: thrombus-targeted fibrinolysis. Semin Thromb Hemost 2013; 39 (1) 48-58
    PubMedGoogle Scholar
  • 9 Cannon CP. Exploring the issues of appropriate dosing in the treatment of acute myocardial infarction: potential benefits of bolus fibrinolytic agents. Am Heart J 2000; 140 (6, Suppl): S154-S160
    CrossrefPubMedGoogle Scholar
  • 10 Mehta RH, Alexander JH, Van de Werf F , et al. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. JAMA 2005; 293 (14) 1746-1750
    CrossrefPubMedGoogle Scholar
  • 11 Bristow AF, Barrowcliffe T, Bangham DR. Standardization of biological medicines: the first hundred years, 1900-2000. Notes Rec R Soc Lond 2006; 60 (3) 271-289
    CrossrefPubMedGoogle Scholar
  • 12 World Health Organization. Recommendations for the Preparation, Characterization and Establishment of International and Other Biological Reference Standards (revised 2004). WHO Technical Report Series, No. 932. 2006
    PubMedGoogle Scholar
  • 13 Marder VJ, Novokhatny V. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential. J Thromb Haemost 2010; 8 (3) 433-444
    CrossrefPubMedGoogle Scholar
  • 14 Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J 2007; 34 (3) 318-327
    PubMedGoogle Scholar
  • 15 Bangham DR, Walton PL. The international standard for streptokinase-streptodornase. Bull World Health Organ 1965; 33 (2) 235-242
    PubMedGoogle Scholar
  • 16 Heath AB, Gaffney PJ. A collaborative study to establish the second international standard for streptokinase. Thromb Haemost 1990; 64 (2) 267-269
    PubMedGoogle Scholar
  • 17 Sands D, Whitton CM, Longstaff C. International collaborative study to establish the 3rd International Standard for Streptokinase. J Thromb Haemost 2004; 2 (8) 1411-1415
    CrossrefPubMedGoogle Scholar
  • 18 Longstaff C, Thelwell C, Whitton C. The poor quality of streptokinase products in use in developing countries. J Thromb Haemost 2005; 3 (5) 1092-1093
    CrossrefPubMedGoogle Scholar
  • 19 Hermentin P, Cuesta-Linker T, Weisse J , et al. Comparative analysis of the activity and content of different streptokinase preparations. Eur Heart J 2005; 26 (9) 933-940
    CrossrefPubMedGoogle Scholar
  • 20 Couto LT, Donato JL, de Nucci G. Analysis of five streptokinase formulations using the euglobulin lysis test and the plasminogen activation assay. Braz J Med Biol Res 2004; 37 (12) 1889-1894
    CrossrefPubMedGoogle Scholar
  • 21 Longstaff C, Whitton CM, Stebbings R, Gray E. How do we assure the quality of biological medicines?. Drug Discov Today 2009; 14 (1-2) 50-55
    CrossrefPubMedGoogle Scholar
  • 22 Mahboubi A, Sadjady SK, Mirzaei Saleh Abadi M, Azadi S, Solaimanian R. Biological activity analysis of native and recombinant streptokinase using clot lysis and chromogenic substrate assay. Iran J Pharm Res 2012; 11 (4) 1087-1093
    PubMedGoogle Scholar
  • 23 Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220 (1) 31-38
    CrossrefPubMedGoogle Scholar
  • 24 World Health Organisation. Twenty-first Meeting. Expert Committee on Biological Standardisation. WHO Technical Report Series No. 413. 1968
    PubMedGoogle Scholar
  • 25 White WF, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966; 5 (7) 2160-2169
    CrossrefPubMedGoogle Scholar
  • 26 Philo RD, Gaffney PJ. Assay methodology for urokinase: its use in assessing the composition of mixtures of high- and low-molecular weight urokinase. Thromb Res 1981; 21 (1–2) 81-88
    CrossrefPubMedGoogle Scholar
  • 27 Gaffney PJ, Heath AB. A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA). Thromb Haemost 1990; 64 (3) 398-401
    PubMedGoogle Scholar
  • 28 Gaffney PJ, Curtis AD. A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemost 1985; 53 (1) 134-136
    PubMedGoogle Scholar
  • 29 Gaffney PJ, Curtis AD. A collaborative study to establish the 2nd international standard for tissue plasminogen activator (t-PA). Thromb Haemost 1987; 58 (4) 1085-1087
    PubMedGoogle Scholar
  • 30 Gates J, Hartnell GG. When urokinase was gone: commentary on another year of thrombolysis without urokinase. J Vasc Interv Radiol 2004; 15 (1, Pt 1): 1-5
    CrossrefPubMedGoogle Scholar
  • 31 Sands D, Whitton CM, Merton RE, Longstaff C. A collaborative study to establish the 3rd International Standard for tissue plasminogen activator. Thromb Haemost 2002; 88 (2) 294-297
    PubMedGoogle Scholar
  • 32 PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989; 1 (8643) 863-868
    PubMedGoogle Scholar
  • 33 Kasai S, Arimura H, Nishida M, Suyama T. Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260 (22) 12377-12381
    PubMedGoogle Scholar
  • 34 Hanbücken FW, Schneider J, Günzler WA, Friderichs E, Giertz H, Flohé L. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria. Arzneimittelforschung 1987; 37 (8) 993-997
    PubMedGoogle Scholar
  • 35 Nolli ML, Sarubbi E, Corti A , et al. Production and characterization of human recombinant single chain urokinase-type plasminogen-activator from mouse cells. Fibrinolysis 1989; 3: 101-106
    PubMedGoogle Scholar
  • 36 Lenich C, Pannell R, Henkin J, Gurewich V. The influence of glycosylation on the catalytic and fibrinolytic properties of prourokinase. Thromb Haemost 1992; 68 (5) 539-544
    PubMedGoogle Scholar
  • 37 Munger MA, Forrence EA. Anistreplase: a new thrombolytic for the treatment of acute myocardial infarction. Clin Pharm 1990; 9 (7) 530-540
    PubMedGoogle Scholar
  • 38 Verstraete M. Third-generation thrombolytic drugs. Am J Med 2000; 109 (1) 52-58
    CrossrefPubMedGoogle Scholar
  • 39 Gaffney PJ. Standards in fibrinolysis—current status and future challenges. Thromb Haemost 1995; 74 (6) 1389-1397
    PubMedGoogle Scholar
  • 40 Dunn CJ, Goa KL. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am J Cardiovasc Drugs 2001; 1 (1) 51-66
    CrossrefPubMedGoogle Scholar
  • 41 Armstrong PW, Burton JR, Palisaitis D , et al. Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). Am Heart J 2000; 139 (5) 820-823
    PubMedGoogle Scholar
  • 42 Armstrong PW, Burton J, Pakola S , et al; CAPTORS II Investigators. Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS II). Am Heart J 2003; 146 (3) 484-488
    CrossrefPubMedGoogle Scholar
  • 43 Laroche Y, Heymans S, Capaert S, De Cock F, Demarsin E, Collen D. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood 2000; 96 (4) 1425-1432
    PubMedGoogle Scholar
  • 44 Verhamme P, Goossens G, Maleux G, Collen D, Stas M. A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion. J Thromb Thrombolysis 2007; 24 (1) 1-5
    CrossrefPubMedGoogle Scholar
  • 45 Marder VJ, Landskroner K, Novokhatny V , et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86 (3) 739-745
    PubMedGoogle Scholar
  • 46 Sottrup-Jensen L, Claeys H, Zajdel M, Petersen T, Magnusson S. The primary structure of human plasminogen: isolation of two lysine-binding fragments and one “mini” plasminogen (MW 38000) by elastase-catalyzed specific limited proteolysis. In: Progress in Chemical Fibrinolysis and Thrombolysis. New York, NY: Raven Press; 1978: 191-209
    Google Scholar
  • 47 Wu HL, Shi GY, Wohl RC, Bender ML. Structure and formation of microplasmin. Proc Natl Acad Sci U S A 1987; 84 (24) 8793-8795
    CrossrefPubMedGoogle Scholar
  • 48 Marder VJ, Manyak S, Gruber T , et al. Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2-5. Thromb Haemost 2010; 104 (4) 780-787
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Deitcher SR, Funk WD, Buchanan J, Liu SC, Levy MD, Toombs CF. Alfimeprase: a novel recombinant direct-acting fibrinolytic. Expert Opin Biol Ther 2006; 6 (12) 1361-1369
    CrossrefPubMedGoogle Scholar
  • 50 Tsui I, Pan CK, Rahimy E, Schwartz SD. Ocriplasmin for vitreoretinal diseases. J Biomed Biotechnol 2012; ; doi: 10.1155/2012/354979
    PubMedGoogle Scholar
  • 51 Kirkwood TBL, Campbell PJ, Gaffney PJ. A standard for human plasmin. Thromb Diath Haemorrh 1975; 34 (1) 20-30
    PubMedGoogle Scholar
  • 52 Johnson AJ, Kline DL, Alkjaersig N. Assay methods and standard preparations for plasmin, plasminogen and urokinase in purified systems, 1967-1968. Thromb Diath Haemorrh 1969; 21 (2) 259-272
    PubMedGoogle Scholar
  • 53 Gaffney PJ, Mussett MV. International collaborative study for the establishment of the second International Reference Preparation of plasmin. Thromb Haemost 1983; 50 (3) 645-649
    PubMedGoogle Scholar
  • 54 Chase Jr T, Shaw E. p-Nitrophenyl-p'-guanidinobenzoate HCl: a new active site titrant for trypsin. Biochem Biophys Res Commun 1967; 29 (4) 508-514
    CrossrefPubMedGoogle Scholar
  • 55 Panteghini M, Forest JC. Standardization in laboratory medicine: new challenges. Clin Chim Acta 2005; 355 (1–2) 1-12
    CrossrefPubMedGoogle Scholar
  • 56 Jackson CM, White II GC, Barrowcliffe T , et al; Joint Committee of the IFCC Scientific Division and the ISTH Scientific and Standardization Committee. A reference system approach to future standardization of laboratory tests for hemostasis. A position paper of the Joint Committee of the IFCC Scientific Division and the ISTH Scientific and Standardization Committee. Thromb Haemost 2002; 87 (1) 165-169
    PubMedGoogle Scholar
  • 57 Longstaff C, Whitton CM. A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units. J Thromb Haemost 2004; 2 (8) 1416-1421
    CrossrefPubMedGoogle Scholar
  • 58 Longstaff C, Whitton C, Thelwell C, Belgrave D ; Fibrinolysis Subcommittee of the SSC of the ISTH. An international collaborative study to investigate a proposed reference method for the determination of potency measurements of fibrinolytics in absolute units. J Thromb Haemost 2007; 5 (2) 412-414
    CrossrefPubMedGoogle Scholar
  • 59 Urano T, Urano S, Castellino FJ. Reaction of tissue-type plasminogen activator with 4-methylumbelliferyl-p-guanidinobenzoate hydrochloride. Biochem Biophys Res Commun 1988; 150 (1) 45-51
    CrossrefPubMedGoogle Scholar
  • 60 Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost 2007; 5 (4) 804-811
    CrossrefPubMedGoogle Scholar
  • 61 Hubbard AR, Dodt J, Lee T , et al; Factor VI I I and Factor IX Subcommittee of The Scientific and Standardisation Committee of The International Society on Thrombosis and Haemostasis. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost 2013; 11 (5) 988-989
    CrossrefPubMedGoogle Scholar